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AAV: Adeno-associated virus 
BaEV: Baboon envelope proteins  
BCL11A: B-cell lymphoma/leukemia 11A 
Cas9: CRISPR associated protein 9 
CRISPR: Clustered regulatory interspaced short palindromic repeats 
CsH: Cyclosporin H 
DSB: Double-strand break 
FDA: Food and Drug Administration 
GvHD: Graft-versus-host disease  
HbA: Adult hemoglobin 
HBB: β-globin gene  
HbF: Fetal hemoglobin  
HBG1: Hemoglobin subunit gamma 1 
HBG2: Hemoglobin subunit gamma 2 
HDR: Homology direct repair 
HPFH: Hereditary persistence of fetal hemoglobin  
HSCT: Hematopoietic stem cell transplantation 
HSPCs: Hematopoietic stem and progenitor cells 
IGF2BP1: Insulin-like growth factor 2 mRNA binding protein-1  
KLF1: Kruppel-like Factor 1 
LVs: Lentiviral vectors 
MOI: Multiplicity of infection 
NHEJ: Non-homologous end joining 
SCD: Sickle cell disease  
sgRNA: Single guide ribonucleic acid 
shmiR: MicroRNA-embedded shRNA  
ssODN: Single-stranded-oligodeoxynucleotide 
TALENs: Transcription activator-like effector nucleases 
VCN: Vector copy number 
VSV-G: Vesicular-stomatitis-virus glycoprotein  




Different mutations in the β-globin gene cause one of the most frequent single-gene 
disorders worldwide known as β-hemoglobinopathies. Initial therapeutic approaches 
consisted of the introduction of a wild-type copy of the β-globin gene by vectors 
(LVs). However, the induction of fetal hemoglobin (HbF, α2γ2) by LVs and other 
molecular approaches, reproducing the benign condition referred to as hereditary 
persistence of fetal hemoglobin (HPFH), has become a promising alternative 
treatment for these blood disorders. 
There is a big disparity of opinions to determine the most efficient and reliable 
gene therapy for inherited diseases such as β-hemoglobinopathies. While generally 
LVs seem to be the strategy of choice for disorders where high expression of the 
transgene is needed to ensure therapeutic effects, CRISPR/Cas9 looks more 
favorable for diseases where controlled gene expression is essential. However, both 
techniques present disadvantages, including insertional mutagenesis for LVs, and 
possible off-target cutting for CRISPR/Cas9 gene editing. 
In this study, a head-to-head comparative analysis of different gene therapy 
approaches was performed utilizing LVs and CRISPR/Cas9 to promote HbF 
production and determined their limitations, efficacy, and safety profile for the 
treatment of β-hemoglobinopathies. LVs encoding for 1) γ-globin gene, 2) IGF2BP1, 
and 3) miRNA-embedded shRNA for BCL11A, were tested. To enhance viral 
transduction efficiency in HSCs, two novel baboon envelope proteins (BaEV) were 
compared to the highly used vesicular-stomatitis-virus-G protein (VSV-G). On the 
other hand, the CRISPR/Cas9 system was employed to knock-down KLF1 and 
BCL11A genes involved in HbF repression, and to disrupt the binding site of different 
transcription factors in the γ-globin gene (HBG1/2) promoter. 
Two tested VSV-G lentiviral strategies (IGF2BP1 and miRNA-embedded 
shRNA for BCL11A) yielded the highest HbF levels among all approaches (~50%) 
with clinically relevant VCNs (<2) and no impaired differentiation. VSV-G γ-globin 
lentivirus treatment showed 20% HbF induction and relevant VCN, whereas all 
BaEV-LVs induced weaker HbF resurgence. Alternatively, BCL11A and HBG1/2 
CRISPR/Cas9 gene disruption approaches also generated therapeutic HbF levels 
(~40%), showed low off-targets effect, weak transcript impairment, and no adverse 
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effect during hematopoiesis. KLF1 gene editing showed stronger gene dysregulation 
and lower HbF resurgence. 
Based on our findings, we endorse BCL11A and HBG1/2 gene disruption 
approaches as the most promising strategies to be applied in the clinic due to their 
safety profile and high efficacy. On the other hand, VSV-G envelope protein and the 
γ-globin construct might be the safest LV strategy for β-hemoglobinopathies to be 
implemented in clinical studies. Nonetheless, γ-globin gene addition depends on 
efficient transgene expression, and therefore, alternative strategies to reverse the 
fetal-to-adult hemoglobin switch, such as BCL11A knockdown or IGF2BP1 





Verschiedene Mutationen im β-Globin-Gen sind die Ursache für eine der weltweit 
häufigsten Einzelgenstörungen, die als β-Hämoglobinopathien bekannt sind. 
Anfängliche therapeutische Ansätze bestanden in der Einführung einer gesunden 
Kopie des β-Globin-Gens mittels lentiviraler Vektoren (LVs). Die Induktion von 
fötalem Hämoglobin (HbF, α2γ2) durch LVs und andere molekulare Ansätze, die die 
gutartige erbliche Persistenz von fötalem Hämoglobin (HPFH) reproduzieren, ist 
jedoch eine vielversprechende alternative Behandlung für diese Bluterkrankungen 
geworden. 
Es gibt große Meinungsverschiedenheiten, um die effizienteste und 
zuverlässigste Gentherapie für Erbkrankheiten wie β-Hämoglobinopathien zu 
bestimmen. Während LVs im Allgemeinen die Strategie der Wahl für Krankheiten zu 
sein scheinen, bei denen eine hohe Transgenexpression für therapeutische 
Wirkungen erforderlich ist, sieht CRISPR/Cas9 für Erkrankungen, bei denen eine 
kontrollierte Genexpression wesentlich ist, günstiger aus. Beide Techniken weisen 
jedoch Nachteile auf, einschließlich Insertionsmutagenese für LVs und mögliches 
Schneiden außerhalb des Ziels für die CRISPR/Cas9-Geneditierung. 
In dieser Studie führten wir eine Kopf-an-Kopf-Vergleichsanalyse 
verschiedener gentherapeutischer Ansätze unter Verwendung von LVs und 
CRISPR/Cas9 durch, um die HbF-Produktion zu fördern, und bestimmten deren 
Grenzen, Wirksamkeit und Sicherheitsprofil für die Behandlung von β-
Hämoglobinopathien. LVs Kodifizierung für 1) γ-Globin-Gen, 2) IGF2BP1 und 3) in 
miRNA eingebettete shRNA für BCL11A, wurden getestet. Um die Effizienz der 
Virusübertragung in HSCs zu verbessern, wurden zwei neuartige Pavianhüllproteine 
(BaEV) mit dem häufig verwendeten vesikulären Stomatitis-Virus-G-Protein (VSV-G) 
verglichen. Andererseits wurde das CRISPR/Cas9-System eingesetzt, um KLF1- und 
BCL11A-Gene, die an der HbF-Repression beteiligt sind, abzubauen und die 
Bindungsstelle mehrerer Transkriptionsfaktoren im Promotor des γ-Globin-Gens 
(HBG1 / 2) zu stören. 
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Zwei getestete lentivirale VSV-G-Strategien (IGF2BP1 und miRNA-
eingebettete shRNA für BCL11A) ergaben die höchsten HbF-Spiegel unter allen 
Ansätzen (~ 50%) mit klinisch relevanten VCNs (<2) und keine beeinträchtigte 
Differenzierung. Die Behandlung mit VSV-G-γ-Globin-Lentivirus zeigte eine 20% ige 
HbF-Induktion und relevante VCN, während alle BaEV-LVs ein schwächeres HbF-
Wiederaufleben induzierten. Andererseits erzeugten BCL11A- und HBG1/2-
CRISPR/Cas9-Genstörungsansätze auch therapeutische HbF-Spiegel (~40%), 
zeigten einen geringen Off-Target-Effekt, eine schwache Transkriptbeeinträchtigung 
und keinen nachteiligen Effekt während der Hämatopoese. Alternativ zeigte die 
KLF1-Geneditierung eine stärkere Gendysregulation und ein geringeres 
Wiederaufleben von HbF. 
Basierend auf unseren Erkenntnissen unterstützen wir BCL11A- und HBG1/2-
Genstörungsansätze als die vielversprechendsten Strategien, die aufgrund ihres 
Sicherheitsprofils und ihrer hohen Wirksamkeit in der Klinik angewendet werden 
können. Andererseits könnten das VSV-G-Hüllprotein und das γ-Globin-Konstrukt die 
sicherste LV-Strategie für β-Hämoglobinopathien sein, die in klinischen Studien 
implementiert werden können. Nichtsdestotrotz leidet die Zugabe von γ-Globin-
Genen unter einer effizienten Transgenexpression, und daher können alternative 
Strategien zur Umkehrung des Hämoglobin-Wechsels von Fötus zu Erwachsenem, z. 
BCL11A Knockdown, IGF2BP1-Überexpression, untersucht und verbessert werden 
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The most common inherited monogenic diseases are β-hemoglobinopathies, 
encompassing β-thalassemia and Sickle cell disease (SCD), with an estimated 
incidence of 275,000 newborns with SCD and 56,000 with β-thalassemia major every 
year.1 Approximately 7% of the global population is a carrier of the disease, mainly in 
Mediterranean countries, Africa, the Middle East, Southeast Asia, and India.2 Also, β-
hemoglobinopathies have become much more common in North America and Europe 
in the past decades due to immigration.3 
These diseases are characterized by a defective (β+) or absent (β0) production 
of the beta chain of hemoglobin. This can be triggered by more than 300 possible 
mutations identified up to now in the human β-globin gene (HBB) on chromosome 
11,4 which consists of three exons and two introns with a total length of 1,600 bp 
(Figure 1). One specific mutation in HBB at codon 6 (glutamine > valine) results in a 
structurally altered protein that undergoes polymerization, leading to a sickle form of 
the red blood cell causing SCD.5 
 
 
Figure 1. Representation of the globin gene cluster and the most common point mutations in the HBB 
gene causing β-hemoglobinopathies. Point mutations are localized in the promoter ( ), the CAP site 
(*), the 5'-untranslated region (•), the initiation codon (1), each of the three exons ( ), defective RNA 




β-thalassemia is an autosomal recessive disorder, and therefore, only 




(thalassemia major, β0β0) clinical symptoms. Mutations induce erythropoiesis 
perturbations, high apoptosis of red blood cells, and subsequent anemia.7 The 
disturbed expression of β-globin is compensated by α-globin up-regulation that 
generates intracellular aggregations of hemoglobin in erythroid precursor cells.8 
Symptoms of disease include fatigue, headaches, and dizziness at early stages, 
which further develop to skeletal deformities and hepatosplenomegaly.9 
Consequently, patients rely on life-long blood transfusions with accompanying 
infections and iron overload.10 Blood transfusions are necessary every 3-4 weeks 
and the life expectancy of patients with major thalassemia is significantly reduced, 
where most patients die at the age of 30 to 40 due to organ dysfunction. 
Even though allogeneic hematopoietic stem cell transplantation (HSCT) is a 
healing approach for β-hemoglobinopathies, its success depends on several factors 
including the recipient’s disease, graft selection, graft-versus-host disease (GvHD), 
and complications resulting from immune suppression.11,12 Most importantly, the 
majority of patients do not find a suitable HLA-matched donor, whilst the lack of 
therapy access and high costs make it especially hard for patients in the most 
affected areas to get the treatment. Only an estimated 10% of patients with β-
hemoglobinopathies get treated by allogenic HSCT, and therefore, it becomes highly 
important to develop efficient universal treatment alternatives to cure this type of 
diseases. 
In the last decades, a gene therapy lentivirus approach in combination with 
autologous HSCT has become a great alternative to allogeneic HSCT to treat 
patients with β-hemoglobinopathies.13 This novel therapeutic approach consisted in 
the introduction of a wild-type β-globin gene by means of lentiviral vectors.14 As a 
matter of fact, treated patients with β-hemoglobinopathies showed clinical benefit 
during the first clinical trials after HBB-encoding lentiviral gene therapy 
(NCT01639690, NCT02151526, and NCT02453477).15 
Instead, different studies have demonstrated that fetal hemoglobin (HbF; 
2α2γ) can bind oxygen with superior affinity than adult hemoglobin (HbA; 2α2β) and it 
is functional when reactivated in adults.10,16,17 Individuals with the benign condition 
called hereditary persistence of fetal hemoglobin (HPFH) are characterized by 
increased HbF caused by mutations in the promoter of the hemoglobin gamma gene 
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(HBG) or large deletions in HBB.18 In β-thalassemia patients with HPFH, it has been 
observed that >20% of HbF expression could reduce the disease severity of β-
hemoglobinopathies.19 Thus, bearing in mind this 20% as the minimum therapeutic 
percentage of HbF expression, the most relevant gene therapy approaches to 
overexpress HbF have been compared and evaluated for this thesis as possible 
treatments for β-hemoglobinopathies. 
 
4.2. Gene therapy approaches to promote fetal hemoglobin production 
The expression of the different globin genes is regulated by the locus control region 
(LCR) and a number of repressors and enhancers. The most important regulators are 
KLF1 and BCL11A, which are involved in the γ- to β-globin switching process, 
directly increasing β-globin expression and down-regulating γ-globin (Figure 2).20 The 
great success showed by earlier β-globin-encoding lentiviral clinical trials has sparked 
novel alternative strategies to overexpress γ-globin. Numerous research groups have 
developed different approaches in the last decade, either by means of lentivirus 
vectors 21-25 or by targeting regulators involved in the Fetal to Adult hemoglobin 
switching utilizing the CRISPR/Cas9 system.20,26,27 
 
4.2.1. Lentiviral gene transfer for HbF resurgence 
In the mid-80s, gene transfer through retroviruses arose as a suitable treatment for 
blood disorders,28 where lentiviruses derived from the human immunodeficiency virus 
(HIV) were selected because of their capacity to transduce dividing and non-dividing 
cells, lower genotoxicity, and up to 9kb transgene-carrying capacity.29-31 Also 
advantageous is the possibility to design lentiviral vector carrying particular regulatory 
elements from a specific cell type to control the transgene expression.4 Important to 
note is the number of integration events per cell or vector copy number (VCN) to 
achieve gene expression levels comparable to normality and reduce the likelihood to 
have insertional mutagenesis. As stipulated by the U.S. Food and Drug 
Administration (FDA), the VCN should be lower than five integration events per cell.32 
Nonetheless, gene therapy by lentivirus gene transfer imposed some risks that have 
been reduced with the development of self-inactivating (SIN) vectors by deleting the 
enhancer/promoter regions of the long terminal repeat (LTR).33,34 
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A number of different lentiviral vectors and constructs have been tested in 
recent years to overexpress HbF as a possible treatment option for β-
hemoglobinopathies.21-25 For our study, we have compared the most relevant HbF-
inducing LV vectors encoding for: 1) IGF2BP1 (insulin-like growth factor 2 mRNA-
binding protein-1), a recently discovered fetal-to-adult hemoglobin switching factor, 2) 
miRNA-embedded shRNA specific for the γ-globin repressor protein BCL11A, and 3) 
γ-globin gene under the influence of the β-globin gene promoter (Figure 2). 
 
 
Figure 2. Different lentiviral treatment options used in this investigation to promote fetal hemoglobin 
production for the treatment of β-hemoglobinopathies, including lentivectors encoding for: 1) IGF2BP1, 
a fetal-to-adult hemoglobin switching factor; 2) miRNA-embedded shRNA specific for the γ-globin 
repressor BCL11A, and 3) the γ-globin gene under the influence of the β-globin promoter. KLF1 is a 
transcription factor that positively regulates BCL11A and the expression of the β-globin gene. 
IGF2BP1 and the BCL11A-miRNA-embedded shRNA silence the expression of BCL11A, and 
therefore, γ-globin is expressed. The mutated β-globin gene is represented with blue stripes. Modified 
from Antony et al. (2018).
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Furthermore, an innovative baboon envelope protein (BaEV) has been 
compared to the more frequently used vesicular-stomatitis-virus-G protein (VSV-G)-
LVs, since the former has shown several transduction advantages in CD34+ HSCs. 
Baboon pseudotyped vectors utilized two viral entry receptors (ASCT-1 and ASCT-2) 




HSCs. Therefore, fewer viral particles are required, resulting in reduced cytotoxicity 
and genotoxicity.35-37 A BaEV mutant version lacking the R peptide which inhibits viral 
entry (BaEV-RLess) was also included in our study due to its superior transduction 
potential when compared to the wild-type BaEV.35 With our study we aimed to finalize 
the most promising therapeutic strategy for β-hemoglobinopathies by performing a 
head-to-head comparison of LV vectors with the capacity to increase HbF in HSCs. 
 
4.2.2. CRISPR/Cas9 gene disruption for HbF resurgence 
Although novel constructs have improved the safety of lentiviral gene therapy, the 
risk of insertional mutagenesis is still present. As a matter of fact, one β-thalassemia 
patient developed a myeloid-biased cell dominant clone expansion because the 
therapeutic HBB construct integrated adjacently to an oncogene. Nonetheless, this 
patient did not develop leukemia during the next years.38 
Gene editing is a seemingly advantageous alternative to lentiviral gene 
transfer which consists in the introduction of double-strand breaks (DSBs) in the 
DNA, which activates two different types of cell repair mechanisms: 1) non-
homologous end-joining (NHEJ) and 2) homology-directed repair (HDR). NHEJ takes 
place more frequently and leads to insertion and deletions (InDels) of nucleotides 
due to prompt DNA repair, hence changing the gene reading frame and hindering 
gene transcription and/or translation.39 On the contrary, HDR events occur at a low 
rate and results in the correction of the gene by homologous recombination with the 
sister chromatid.40 Therefore, NHEJ can be applied to disrupt target genes after 
DSBs. The most utilized tools to induce DSBs are: 1) transcription activator-like 
effector nucleases (TALENs), 2) zinc finger nucleases (ZFNs) and 3) the 
CRISPR/Cas9 system. TALENs and ZFNs have high specificity and fidelity; however, 
they require intricate protein manufacturing, making their production time-consuming 
and costly.41 In our recent study, we carried out a comparison of these three 
techniques and observed that CRISPR/Cas9 offered a more efficient on-target gene 
editing.42 The CRISPR/Cas9 system comprises an endonuclease (Cas9) and a single 
guide RNA (sgRNA), and is at the moment the most popular gene-editing tool.  The 
complete CRISPR system can be delivered by a single electroporation of the mRNA 
or ribonucleoprotein (RNP) to sufficiently attain high gene editing efficiencies and low 
cytotoxicity.43 On the other hand, this system also presents the risk of undesirable 
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DSBs in other loci, or what is known as off-targets. Therefore, assessing the safety 
profile of the CRISPR system should always be required for every gene editing 
therapeutic approach.44 In the last years, several techniques have been developed to 
determine the number of off-targets, including ChIP-seq, Digenome-seq, BLISS, 
BLESS, CIRCLE-seq, and GUIDE-seq.45-51 
Recent gene-editing clinical trials are very effective in ameliorating the 
symptoms of β-hemoglobinopathies by inducing the production of HbF and mimic 
individuals with HPFH (NCT03655678, NCT03745287; Figure 3). The CRISPR/Cas9 
approach utilized in these clinical trials consists in HSCT of β-thalassemia HSCs after 
disrupting the BCL11A enhancer. In our study, we have evaluated the efficacy and 
safety profile of this approach and two other promising CRISPR/Cas9-gene 
disruption approaches to promote HbF resurgence for the treatment of β-
hemoglobinopathies. In brief, these strategies consist in gene disruption of: 1) 
BCL11A, a γ-globin gene repressor; 2) KLF1, a transcription factor that positively 
regulates BCL11A, and 3) the binding site of BCL11A located in the HBG1/2 
promoter (Figure 3). 
 
Figure 3. Molecular regulators involved in the fetal (HbF) to adult (HbA) hemoglobin switch and 
CRISPR/Cas9 gene disruption strategies carried out in our study to promote HbF production as a 
remedy for β-thalassemia and SCD. The β-globin gene cluster, located in chromosome 11, consists in: 
locus control region (LCR), epsilon globin (HBE), 2 subunits of gamma globin (HBG1/2), delta globin 
(HBD), and beta globin (HBB). The α-globin gene cluster, located in chromosome 16, comprises zeta 
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globin (HBZ) and two subunits of alpha globin (HBA). In our study we utilized the CRISPR/Cas9 
system to gene disrupt: (1) the gamma globin repressor BCL11A, (2) KLF1, and (3) the binding site of 
BCL11A in the promoter of HBG1/2. (4) Representation of hereditary persistence of HbF (HPFH) 
benign condition, which can be caused by a 13bp deletion in the γ-globin promoter or by a large 13kb 





5. Aim of the study 
β-hemoglobinopathies are the most common inherited monogenic diseases, hence it 
is of high importance to determine the safest and most efficient gene therapy for the 
treatment of these diseases.  For this study, the main objective was to perform a 
side-by-side comparison of different gene therapy approaches to promote fetal 
hemoglobin production and evaluate their efficiency and safety to determine the most 
propitious strategy. 
Nevertheless, there were several other side objectives in this investigation that 
were also achieved. Firstly, a broad lentiviral platform was established to effectively 
produce high viral titers and attain adequate transduction efficiencies in different cell 
lines and primary cells. Additionally, pseudotyping of several lentiviral envelope 
proteins was evaluated to enhance transduction efficiencies depending on the cell 
type. This lentivirus platform is now being used in our research group to study and 
develop treatments for other inherited disorders or for immunotherapy. 
Just as important, we have established a gene-editing GMP-based 
CRISPR/Cas9 platform in our facilities, which has allowed the development of 
several new gene therapy investigations within our group, including very 
sophisticated approaches such as gene correction and gene addition for the 
treatment of not only β-hemoglobinopathies, but also neurometabolic diseases like 
metachromatic leukosdistrophy (MLD) and other genetic disorders. 
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6. Results and Discussion 
6.1. Lentiviral gene transfer: Comparative analysis of lentiviral gene transfer 
approaches designed to promote fetal hemoglobin production for the treatment 
of β-hemoglobinopathies (paper 1) 
The resurgence of HbF as a treatment for β-hemoglobinopathies is a suitable 
alternative to β-globin gene transfer because β-thalassemia patients presenting the 
benign condition HPFH show minor symptoms of disease when they have at least 
20% of HbF in blood, confirming the therapeutic potential of this approach. However, 
gene transfer efficiency and transgene expression are big challenges that need to be 
amended for β-globin and γ-globin gene addition. Thus, alternative strategies to 
reverse the fetal-to-adult hemoglobin switch, need to be explored and further 
optimized as future and more efficient treatment options. For this reason, BCL11A 
knockdown and IGF2BP1 overexpression have been included in this study. Also, 
previous studies showed several benefits of baboon envelope proteins over the 
generally employed VSV-G, such as higher tropism in HSCs and lower genotoxicity, 
which could aid in improving lentiviral gene transfer for the treatment of these blood 
disorders.35,36,52 
Up to date, no one-to-one comparative analysis of different HbF-inducing LV 
constructs has been carried out in HSCs to determine their therapeutic potential for 
β-hemoglobinopathies, nor pseudotyping of these LV constructs with different 
envelope proteins has been performed in order to assess efficacy and suitability 
towards clinical translation. In our study, we have conducted a thorough comparative 
analysis of different HbF-inducing LV constructs and envelope proteins, while we 
have suggested the most efficient and safest therapeutic approach for β-
hemoglobinopathies based on our results. 
 
6.1.1. Lentivirus production 
First, we optimized our virus production platform using three different envelope 
proteins (VSV-G, BaEV-RLess, BaEV) and a GFP-encoding construct under the 
influence of a PGK promoter. The most efficient lentivirus production procedure we 
established, based on the protocol developed by Girard-Gagnepain,35 was selected 
in accordance with the titer. Our results demonstrated that titers measured by cell 
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culture titration were on average an 86 and 56 fold higher for VSV-G over BaEV-
RLess and BaEV envelope proteins, respectively. However, viral titers calculated by 
p24 ELISA kit and qPCR did not show such differences as before, but <4-fold higher 
infectious units (IFU) for VSV-G over both BaEV envelopes measured by ELISA, and 
<5-fold higher by qPCR. 
Cell culture titration was selected as the most consistent titration method 
because only the functional viral particles are taken into account. ELISA and qPCR 
methods overestimated baboon-pseudotyped viral titer probably due to the presence 
of non-functional or empty baboon lentiviral particles. Similar incomplete assembly 
has been reported earlier for baboon pseudotyped lentiviruses.53 We also noticed a 
clear effect of insert size on the transduction efficiency of baboon-pseudotyped 
lentiviral vectors. Large constructs (pLVX-IGF2BP1; 7kb) hamper virus production in 
comparison to smaller constructs (pCL20-BCL11A-siRNA; 4kb), hence determining 
the number of functional particles. This finding implies a lower cargo capacity of 
baboon-pseudotyped lentiviruses; however, further studies to identify limitations and 
improve baboon envelopes are needed since its positive tropism in HSCs makes 
them promising candidates to substitute VSV-G in future clinical trials. In a nutshell, 
our results showed superior performance of VSV-G compared to baboon 
counterparts. 
 
6.1.2. Transduction efficiency 
We assessed the transduction efficiency of these three envelope proteins with a 
GFP-encoding LV construct in Lenti-X 293T cells and found that VSV-G envelope 
showed very high transduction efficiency (99 ± 0.05% GFP+ cells), while BaEV-RLess 
(77 ± 1.1%) and BaEV (66 ± 2.2%) resulted in lower but adequate level of 
transduction. We extended our transduction analysis to other cell types including K-
562 human erythroleukemia cells and CD34+ HSPCs, where high transduction 
efficiency (78-94%) with baboon envelopes in K-562 cells was detected. However, in 
the clinically relevant CD34+ HSPCs, lower transduction efficiency (40-58%) was 
observed with BaEV envelopes. Therefore, a transduction enhancer (RetroNectine) 
and a concentrator were employed to improve transduction efficiencies. However, 
there was no significant improvement in comparison to ultracentrifugation. On the 
other hand, transduction of HSPCs in the presence of Cyclosporine H (CsH) 
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increased efficiencies with VSV-G (18.6%), BaEV-RLess (25.3%), and BaEV (7.5%), 
and therefore, CsH was employed in all following experiments. 
 Consequently, this already established transduction procedure was used with 
the therapeutic constructs pLVX-IGF2BP1, pCL20-BCL11A-shRNA and pCL20-γ-
globin to assess their transduction efficiency. As explained above, the transgene size 
has an effect on virus production, and therefore, significant differences in 
transduction efficiencies for different constructs can be expected. All three constructs 
comprise erythroid-specific promoters; ergo, K562 cell culture titration was employed 
to determine the viral titers, whilst transduction for the constructs incorporating a GFP 
reporter gene was determined by flow cytometry on day 7 post-transduction. 
Interestingly, pCL20-BCL11A-shRNA lentiviral particles showed high transduction for 
VSV-G (92 ± 1.1%), adequate level for BaEV-RLess (30 ± 0.7%) and low level for 
BaEV (14 ± 0.6%). On the contrary, pLVX-IGF2BP1 showed minor transduction 
efficiency for baboon envelopes except for VSV-G (75.6 ± 0.3%). 
According to previous studies, baboon envelope proteins exhibit higher 
tropism in HSPCs, hence lead to higher transduction with lower amount of infectious 
units (IFU), which reduces the risk of multicopy integration and insertional 
mutagenesis.35-37,52 Our results verified this observation, since the RLess baboon 
envelope exhibited, at multiplicity of infection (MOI) 20, >60% transduction efficiency 
in HSPCs, while using VSV-G higher MOIs were needed to reach the same 
efficiency. BaEV-RLess, characterized by the deletion of the R peptide, outperformed 
BaEV in all types of cells and treatments as stated before in earlier investigations.35 
Finally, the VCN was clinically relevant as a maximum of ~2 provirus copies per cell 
were detected for all treatments, reducing the risk of insertional mutagenesis. 
 
6.1.3. γ-Globin up-regulation and HbF expression 
We determined the functional outcome of our transgene overexpression through 
qPCR and hemoglobin electrophoresis. The gene expression analysis through qPCR 
results exhibited high level of γ-globin transcripts in all treatments with VSV-G 
envelope, where a 3-fold increase was detected for pLVX-IGF2BP1 and pCL20-
BCL11A-siRNA, whilst pCL20-γ-globin led to ~1.8-fold increment. As the VSV-G-
pCL20-BCL11A-shRNA treatment employs shRNA to repress the expression of 
BCL11A transcripts, the qPCR data confirmed >2-fold decrease in BCL11A levels. 
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Transcript analysis for IGF2BP1 also indicated remarkable upregulation of IGF2BP1 
(~5*103 fold) in the VSV-G-pLVX-IGF2BP1 treatment since this fetal-specific gene is 
expressed at very low levels in adult cells. However, in the baboon-pseudotyped 
treatments, no apparent γ-globin up-regulation was detected at mRNA level. 
At protein level, we assessed HbF expression by HPLC and found a 
considerable rise in HbF for all transduced treatments when compared to untreated 
CD34+ HSCs (6 ± 1.8%). Remarkably, the highest HbF expression was detected in 
VSV-G treatments for pLVX-IGF2BP1 (50 ± 1.6%) and pCL20-BCL11A-siRNA (50 ± 
6.5%), whereas pCL20-γ-globin strategy yielded moderate but still therapeutic levels 
of HbF (20 ± 2.6%). Considering HbF expression per VCN, IGF2BP1 transgene 
induced the highest HbF production per provirus copy. As observed at RNA level, 
baboon treatments expressed lower levels of HbF, being BaEV-RLess superior in all 
treatment groups. Therefore, our comparative study showed clinically relevant VCNs 
and therapeutic levels of HbF (>20%) attained using VSV-G envelope, while BaEV-
RLess and BaEV induced weaker HbF resurgence. 
Erythroid differentiation, maturation and proliferation were not hampered in the 
different LV treatments. Flow cytometry analysis found no substantial differences 
between treated samples and the control, where all treatments presented >90% 
CD235+, indicating that all constructs had no apparent effect during our in vitro 
differentiation. However, it is important to mention that each transgene might have its 
own limitations. For instance, the pCL20-BCL11A-siRNA construct includes short 
hairpin RNAs (shRNAs) which were previously associated with endogenous 
dysregulation and cytotoxic effects.54,55 Importantly, BCL11A is involved in 
hematopoiesis and brain development, and thereby, a solid knockdown with shRNA 
could impair erythropoiesis among other negative effects19,56,57. Nonetheless, for the 
time being, no negative effects have been observed after BCL11A knockdown in 
mouse and human HSCs.58 On the other hand, overexpression of IGF2BP1, though 
very effective for HbF resurgence even with low VCN indicating that SPTA1 is a very 
efficient erythroid-specific promoter, could also modulate cell metabolism and 
oncogenesis, and therefore, animal transplantation studies are necessary.59 The 
VSV-G-enveloped pCL20-γ-globin construct presents none of the above explained 
limitations, since there no implication in signaling pathways as with BCL11A and 
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IGF2BP1, but direct up-regulation of HbF. As a matter of fact, this strategy has been 
recently implemented in a clinical trial (NCT02186418). 
In a nutshell, our lentivirus study indicated that VSV-G-pseudotyped LVs have 
superior transduction efficiency in HSCs in comparison to BaEVRLess- and BaEV-
pseudotyped LVs. Out of the three molecular approaches of this investigation, LV-
mediated overexpression of γ-globin stood out over the others due to the associated 
safety concerns. Thus, the LV encoding for γ-globin, together with the VSV-G 
envelope, might be the safest strategy to be implemented in the clinics. However, as 
mentioned above, γ-globin gene addition presents several challenges such as gene 
transfer efficiency and transgene expression. Therefore, BCL11A knockdown or 
IGF2BP1 overexpression, need to be further investigated as alternative and highly 
efficient treatment options. 
 
6.2. CRISPR/Cas9 gene disruption: Comparative targeting analysis of KLF1, 
BCL11A and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal 
hemoglobin (paper 2) 
Lentiviral gene therapy is succeeding in current clinical trials for β-
hemoglobinopathies (NCT02140554, NCT01639690, NCT02453477). Nevertheless, 
as explained above, there is a safety concern due to insertional mutagenesis and 
uncontrolled expression. For that reason, other gene therapy techniques such as 
gene disruption by CRISPR/Cas9 are taking over, mimicking the benign HPFH by 
knocking down genes involved in the HbF-to-HbA globin switch.  
In our study, we have completed a one-to-one comparison of the three most 
promising CRISPR/Cas9 approaches for HbF resurgence as a treatment for β-
hemoglobinopathies, which consists of disrupting three genes: KLF1, BCL11A, and 
HBG1/2 promoters. Furthermore, due to several concerns on the CRISPR/Cas9 
safety, we have also analyzed the off-target effect and transcript dysregulation of 
each approach to determine which strategy has the best safety profile to be applied 




6.2.1. Gene editing 
Our study started optimizing the electroporation protocol necessary to transfect the 
CRISPR/Cas9 components in K-562 cells and CD34+ HSCs. For this purpose, 
DsRed mRNA was transfected under different electroporation settings to identify the 
most efficient setup, achieving >90% of transfection efficiency and viability in both 
cell types. The CRISPR/Cas9 system was next transfected as plasmid and two 
different sgRNAs (T1 and T2) for each target gene were screened. Insertions and 
deletions (InDels) were determined by T7 endonuclease-I (T7E1) assay for KLF1 (T1: 
36 ± 6.5%; T2: 35 ± 5.1%), BCL11A (T1: 22 ± 2.2%; T2: 17 ± 1.4%), and HBG1/2 
(T1: 31 ± 14.4%; T2: 21 ± 6.0%), demonstrating the functionality of the system. 
Besides, all three gene disruption strategies were tested in CD34+ HSPCs, this 
time using Cas9 as RNP and chemically modified sgRNAs as opposed to the 
CRISPR plasmid explained above. Firstly, a variety of sgRNA:Cas9 molar ratios were 
examined and a molar ratio of 2:1 was identified as the most effective in terms of on-
target indels. Secondly, the sgRNAs were tested in HSCs at this ratio and high levels 
of gene editing were observed (63-91%) with the exception of HBG1/2 T1 
(55±10.1%). Finally, gene-edited HSCs were in vitro-differentiated to the erythroid 
lineage for 21 days, whilst no impaired differentiation and proliferation were found. 
 
6.2.2. γ-Globin up-regulation and HbF expression 
To assess the inverse switch from HbA to HbF after gene disruption, we carried out a 
transcript analysis through qRT-PCR, and observed a >4-fold γ-globin up-regulation 
in all treated samples, especially in HBG1/2 gene-disrupted treatment, where >6.5-
fold γ-globin up-regulation was attained. Furthermore, transcripts for KLF1 and 
BCL11A were determined after KLF1 disruption, detecting an evident decrease of 
KLF1 expression (KLF1 T1: 4-fold, KLF1 T2: 2-fold) and consequent BCL11A down-
regulation (2-fold). Likewise, in BCL11A gene-disrupted samples, BCL11A transcript 
expression decreased 2-fold when compared to the control treatment.  
Most importantly, after 21 days of erythroid differentiation of gene-disrupted 
CD34+ HSCs, the HbF expression was analyzed by intracellular staining and HPLC-
mediated hemoglobin electrophoresis. Remarkably, we detected by HPLC that all 
treated samples induced significant levels of HbF over the controls, particularly 
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BCL11A T2 and HBG1/2 T2 yielded HbF levels of 39.5 and 41.9%, respectively. 
Moreover, intracellular staining showed a pronounced increase of HbF+ cells in all 
treated samples, where a strong correlation with HPLC results was observed. 
In individuals with HPFH, several mutations in KLF1 have been observed to 
generate different levels of HbF ranging from 3 to 31%.60 This study is the earliest 
attempt to disrupt KLF1 using CRISPR/Cas9 system, attaining similar HbF levels 
(~25%) as those observed in HPFH patients carrying the mutations K288X or 
S270X.60,61 
Knocking-out BCL11A would impair erythropoiesis and limit the engraftment 
potential, and therefore, in this study, we have carried out a mild knock-down of 
BCL11A by targeting its enhancer (GATAA box).27,62,63 This moderate BCL11A 
knock-down yielded therapeutic level of HbF up to 40% for sgRNA T2 with no 
apparent adverse effect in hematopoiesis. 
Gene disruption of the BCL11A biding site in the HBG1/2 promoters was 
initially executed by Traxler et al.26 The idea is to mimic the 13-bp natural-occurring 
deletion described in a proportion of individuals with HPFH. After gene disruption with 
the CRISPR/Cas9 system, we observed a 13-bp deletion which might probably take 
place through microhomology-mediated end-joining (MMEJ) since this target site is 
flanked by short homology sequences.26,64-66 This approach induced higher HbF level 
than the other strategies, showing an undeniable potential for disease treatment. 
 
6.2.3. Safety profile 
As transcription factors, KLF1 and BLC11A are implicated in numerous signaling 
pathways, hence a detailed transcriptome analysis becomes necessary to determine 
the safety profile of these approaches. All three gene disruption strategies exhibited 
high overall similarity to the control (92% to 99%). However, gene disruption of KLF1 
and HBG1/2 led to 2327 and 2129 genes with impaired transcription, respectively, in 
contrast to BCL11A, where 1017 genes were dysregulated. Furthermore, several 
important genes involved in cell cycle, apoptosis, and different immune pathways 
were disturbed in KLF1- and HBG1/2-treated samples, whilst no oncogenes or tumor 
suppressor genes were dysregulated for BCL11A. 
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As previously explained, the main concern of utilizing the CRISPR/Cas9 
system is the possibility of unwanted off-target sites. For this reason, we have 
performed an in vitro detection of off-targets through GUIDE-seq, after which no off-
targets were detected, with the exception of HBG1/2 sgRNA, where one off-target 
was identified. 
When taking a closer look at our CRISPR/Cas9 gene disruption strategies to 
promote HbF, some important aspects have to be discussed to pinpoint the most 
promising approach to treat β-hemoglobinopathies. Despite KLF1 gene disruption 
secured therapeutic HbF levels with no detected off-targets after GUIDE-seq 
analysis, the enormous dysregulation at RNA level could raise a red flag prior to 
clinical translation. As a matter of fact, there are several previous studies 
demonstrating that disturbances in KLF1 expression have consequences in genes 
involved in cell-cell interaction, microcytosis and cancer.60,67 On the contrary, 
BCL11A gene disruption exhibited a more secure safety profile, where no off-targets 
and a lower gene dysregulation were observed. This approach is currently in a 
clinical trial for the treatment of β-thalassemia (NCT03655678) and SCD 
(NCT03745287) with no negative outcome so far, corroborating our results. Lastly, 
the HBG1/2 gene disruption approach revealed an intermediate safety profile and 
outstanding HbF resurgence, hence this strategy could also be considered as a 
treatment. A recent study has conducted this method in primates, where no toxicity 
was found in blood cells at least during the next 1.5-years.68 
 
6.2.4. Clinical translation 
Another major point for these strategies to be applied to the clinic is to test them in a 
GMP device, in particular the GMP-grade CliniMACS Prodigy (Miltenyi). After 
screening for the most efficacious electroporation setting for HSPCs in the Prodigy 
electroporator using DsRed mRNA, KLF1 T1, BCL11A T2 and HBG1/2 T2 sgRNAs 
were electroporated with this device, attaining high indel rates (54-86%). Also, HbF 
resurgence reached therapeutic levels for all strategies (KLF1 T1: 20 ± 2.8%, 
BCL11A T2: 41 ± 7.8%; HBG1/2 T2: 42 ± 3.6%). These promising results reinsure 




6.3. CRISPR/Cas9-modified Hematopoietic Stem Cells – The future for Stem 
Cell Transplantation (paper 3) 
In this review article, we discuss the therapeutic potential of autologous 
hematopoietic stem cell transplantation (HSCT) after CRISPR/Cas9 gene editing as a 
well-supported alternative to autologous HSCT, since the latter presents several 
limitations e.g. absence of appropriate donor, GvHD, and complications resulting 
from immune suppression. Moreover, detailed information about the most relevant 
gene-editing studies utilizing CRISPR/Cas9 for HSC-related diseases is provided, 
with the purpose to enlighten future gene therapy studies and clinical trials. 
 
In the last section of this review, possible clinical-grade improvements of 
CRISPR/Cas9-mediated autologous HSCT are examined, while future clinical 
perspectives are presented with the intention to give an overview of how this 
promising technology will develop during the next few years. 
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7. Concluding remarks 
There is a big disparity of opinions to determine the most efficient, reliable, and 
accessible gene therapy for inherited diseases such as β-hemoglobinopathies. While 
lentiviral vectors seem to generally be the strategy of choice for diseases where high 
transgene expression is needed for therapeutic effects, CRISPR/Cas9 looks more 
propitious for disorders where controlled gene expression is essential. Nonetheless, 
lentiviruses can be harmful due to insertional mutagenesis and uncontrolled 
expression of the transgene, whereas CRISPR/Cas9 presents unspecific cutting in 
other loci that could generate undesirable effects. 
In this study, we have compared several lentiviral and CRISPR/Cas9 
approaches to promote the production of HbF to treat β-hemoglobinopathies in order 
to have a deeper understanding of their limitations, efficacy, and benefits, with the 
hope to bring some interesting insights that could help to find the most appropriate 
strategy for these blood disorders. On the one hand, we have ascertained that two of 
the tested lentivirus strategies (IGF2BP1 and shmiR for BCL11A) yielded the highest 
HbF levels of all approaches with clinically relevant VCN and no impaired 
differentiation. On the other hand, BCL11A and HBG1/2 CRISPR/Cas9 gene 
disruption generated therapeutic HbF levels, showed low off-target effect, weak 
transcript impairment, and no adverse effect during hematopoiesis. 
Based on our findings, we suggest that BCL11A and HBG1/2 gene disruption 
approaches are the most promising strategies to be applied into the clinics due to 
their safety profile and high efficacy. As a matter of fact, BCL11A gene disruption is 
being studied in clinical trials, where initial data shows successful treatment of 
disease with no reported side effects. Also, an HBG1/2 gene disruption approach is 
under pre-clinical investigation by a leading genome editing company, which is 
expected to start a clinical trial in the near future. Alternatively, it is important to 
mention that γ-globin lentiviral gene transfer strategy is also currently in clinical trial, 
demonstrating its therapeutic potential for the treatment of these diseases.  
During the next years, the outcome of ongoing clinical trials will certainly 
unravel which strategy involved in the resurgence of HbF for the treatment of β-
hemoglobinopathies has a finer safety profile and higher efficacy. However, the gist 
of the matter is for these therapeutic treatments to be accessible in the most affected 
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areas, where the lack of therapy availability and high costs make it especially hard for 
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